{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:02:40Z","timestamp":1768582960784,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:00:00Z","timestamp":1369180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Debate is increasing on whether mycophenolic acid (<jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content>) provides survival benefits comparable to azathioprine (<jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content>) after renal transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study compared safety and efficacy of <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a0662) vs. <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a0267) in low\u2010immunologic\u2010risk kidney transplant recipients (<jats:styled-content style=\"fixed-case\">KTR<\/jats:styled-content>) receiving tacrolimus (<jats:styled-content style=\"fixed-case\">TAC<\/jats:styled-content>) and steroids between 1998 and 2007. Primary outcomes were treatment discontinuation and infection. Secondary endpoints included survival free from biopsy\u2010proven acute rejection, graft loss, death, and renal function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 5\u2010year survival free of treatment discontinuation was higher in the <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> compared to the <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> group (74.1% vs. 60.3%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> was discontinued exclusively because of adverse events (16.4%), while <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> was discontinued primarily for lack of efficacy (21.2%). In univariable analysis, <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> was associated with higher incidence of total (561.5 vs. 667.5 episodes\/1000 person\u2010year, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), bacterial (167 vs. 158 episodes\/1000 person\u2010years, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001), and viral infections (83.2 vs. 100.4 episodes\/1000 person\u2010years, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001), but this association was not confirmed in multivariable analysis. Over 29% of viral infections in the <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> group occurred after conversion to <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content>. A high incidence of tuberculosis was observed (2.9 episodes\/1000 person\u2010years) with a higher incidence (but not a statistically significant difference) in the <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> group. No significant differences were found in patient survival (90% vs. 89%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.78) or graft survival (81% vs. 77.7%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.08), but infection accounted for &gt;50% of all deaths.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The type of antimetabolite, <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content>, was not independently associated with any safety or efficacy outcome 5\u00a0years after transplantation, suggesting that <jats:styled-content style=\"fixed-case\">AZA<\/jats:styled-content> is still a viable option for low\u2010risk <jats:styled-content style=\"fixed-case\">KTR<\/jats:styled-content> receiving <jats:styled-content style=\"fixed-case\">TAC<\/jats:styled-content> and steroids.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12095","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T03:54:34Z","timestamp":1369281274000},"page":"369-378","source":"Crossref","is-referenced-by-count":12,"title":["Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids"],"prefix":"10.1111","volume":"15","author":[{"given":"M.P.","family":"Cristelli","sequence":"first","affiliation":[{"name":"Transplant Division Hospital do Rim e Hipertens\u00e3o UNIFESP S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tedesco\u2010Silva","sequence":"additional","affiliation":[{"name":"Transplant Division Hospital do Rim e Hipertens\u00e3o UNIFESP S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.O.","family":"Medina\u2010Pestana","sequence":"additional","affiliation":[{"name":"Transplant Division Hospital do Rim e Hipertens\u00e3o UNIFESP S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Franco","sequence":"additional","affiliation":[{"name":"Transplant Division Hospital do Rim e Hipertens\u00e3o UNIFESP S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMon043418"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912213212507"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401193100303"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199704150-00013"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92534-1"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199508000-00003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199604150-00008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199701150-00008"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200006150-00033"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16808-6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006101153"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200003150-00028"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02756.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00332.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318199c1c7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg072"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn671"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00299.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0101-28002010000100013"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02101.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318259407f"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl134"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000151632.21551.00"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182130966"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2011.01241.x"},{"key":"e_1_2_6_28_1","unstructured":"Programa Nacional de Controle da Tuberculose.Situa\u00e7\u00e3o Epidemiol\u00f3gica. Portal da Sa\u00fade\u2010Minist\u00e9rio da Sa\u00fade. Available at:http:\/\/portal.saude.gov.br\/portal\/saude\/profissional\/area.cfm?id_area=1527(Accessed 6 February 2011)."},{"key":"e_1_2_6_29_1","volume-title":"Reported tuberculosis in the United States, 2010","author":"CDC","year":"2011"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31820b07ab"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2575"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31825475a3"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12095","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T22:15:13Z","timestamp":1696198513000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/tid.12095"],"URL":"https:\/\/doi.org\/10.1111\/tid.12095","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,22]]}}}